Patent ID: 7557088

Claim:
A composition comprising: a polypeptide comprising SEQ ID NO:1; and a compound selected from the group consisting of: Alvimopan; trans-3,4-dimethyl-4-(3-hydroxyphenly)piperidine; ANTI: 5′-acetamidinoethylnaltrindole; 4-Aminoquinoline; N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide monohydrochloride; Benzimidazolinone; 7-Benzylidenenaltrexone; Binaltorphimine; nor-Binaltorphimine; Butorphanol: 17-cyclobutylmethyl-3,14-dihydroxymorphinan tartrate; CTAP: D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH 2 ; CTOP: D-Phe-Cys-Try-D-Trp-Orn-Thr-Pen-Thr-NH 2 ; Cyclazocine; Cyprodime; 1,3-Dimethyl-4-piperidinone; Ethylketocyclazocine; β-Funaltrexamine; GNTI: 5′-Guanidinonaltrindole; ICI 174864: N,N-diallyl-Tyr-Aib-Aib-Phe-Leu; Indolomorphinan; 5′-Isothiocyanate; J-113397: 1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; JDTic: (3R)-7-Hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinoline-carboxamide; Quadazocine; Loperamide; Methoxynaltrexone; Methylnaltrexone; Mr 2266; Nalmefene: Nalorphine; Naloxone; Naloxone methiodide; Naloxazone; Naltrexone; β-Naltrexamine; Naltriben; Naltrindole; Phenylpiperidine; SB 612111: (5S,7S)-7-{[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl}-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol; SoRI 9409: 5′-(4-chlorophenyl)-17-(cyclopropylmethyl)-6,7-didehydro-3,14-dihydroxy-4,5alpha-epoxypyrido-[2′,3′:6,7]morphinan; SNC 80; TIPP[y]; and Triethyleneglycolnaltrexamine.